drug
abelacimab
Phase 3updated 7mo agoby $NVS NOVARTIS AG
Phase 3community read0 votes
indications
indications
Atrial Fibrillation
all catalysts(0)
nothing on the calendar yet
Trials studying abelacimab
- phase3Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- phase3A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
- phase3A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- phase2Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
News(1)
- Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustmentDespite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.fiercebiotech · 2d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that